Generated by AI
Xencor Inc. is a clinical-stage biopharmaceutical company focused on designing and developing engineered antibody therapeutics for cancer, autoimmune disorders, and other serious diseases. The company’s XmAb protein engineering platform is used to create next-generation antibodies and bispecific molecules with tailored biological activity, supporting a portfolio of proprietary and partnered programs in clinical development. Xencor’s work centers on protein engineering that can improve how therapies interact with immune targets and disease pathways, making it a specialized participant in modern antibody drug innovation. The company also collaborates with external partners to apply its platform across multiple therapeutic areas, including oncology and immunology. Headquartered in Pasadena, California, Xencor Inc. operates as a biotechnology company whose current business is built around research, development, and collaboration in advanced biologic medicines.
Website465 North Halstead Street
Pasadena, CA, 91107
United States
The latest articles about XNCR.
Xencor reported third quarter 2026 net income of US$39.44 million and positive earnings per share, while year to date results still show a net loss of US$111.21 million, underscoring the financial weight of its ongoing research programs. Initial Phase 1b data for subcutaneous plamotamab in rheumatoid arthritis, released at ACR 2026, showed deep B-cell depletion linked with reductions in disease activity. This highlights how Xencor's bispecific platform could extend beyond oncology into...
Summary of Oct 27's posts. Generated by AI.
Summary of Oct 26's posts. Generated by AI.
Summary of Oct 27's posts. Generated by AI.
Investors talking about XNCR also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.